Standard Biotools Inc

This advisory (non‑binding) proposal asks stockholders to approve the Company’s named executive officer compensation as disclosed in the proxy statement, including the Compensation Discussion and Analysis and related tables and narratives. Management seeks this vote to confirm investor support for the design and outcomes of its compensation program, which is heavily weighted toward equity to link pay to long‑term shareholder value and to retain key executives. The filing states the Human Capital Committee used a peer group, an independent compensation consultant, and metrics including revenue and Non‑GAAP OpEx when setting incentives and determining actual payouts. The Board points to historical strong stockholder support for pay (≈98.29% in 2025) and emphasizes pay‑for‑performance alignment, variable compensation mix, clawback policy, and other governance features as reasons to support the program. Although advisory and non‑binding, a significant negative vote would prompt outreach and potential changes by the Human Capital Committee; the Company commits to engage with investors if there is substantial dissent. Key contextual items include recent large equity awards (including long‑term option and RSU grants and one‑time retention RSUs tied to strategic transactions) and material corporate events in 2025–2026 (the SomaLogic divestiture and balance sheet changes) that affected compensation decisions. Investors should weigh the alignment created by equity incentives against dilution and the scale of some one‑time awards when assessing the proposal’s merits. The Board recommends FOR to signal continuity of its pay approach, but stockholders should consider both the compensation design and the outcomes disclosed in the proxy in light of company performance and capital structure changes.

This proposal seeks shareholder approval to adopt the 2026 Equity Incentive Plan, which would provide a new reserve of up to 10 million newly authorized shares plus the rollover of remaining capacity from the existing 2011 Plan (resulting in up to 24,835,928 shares available for grant), and permit inclusion of certain forfeited/expired award shares from the 2011 Plan. Management frames the Plan as necessary to support recruiting, retention, and long‑term alignment of employees, directors and consultants with stockholder interests through equity-based compensation. The Board’s analysis considered historical grant practices, three‑year and projected burn rates, expected 18‑month grant needs (~19.25M forecasted shares), and the dilutive impact (the incremental 10M would increase overhang by ~2.6 percentage points). The Plan includes investor‑oriented governance features (no evergreen increase, no discounted option pricing, clawback, limits on director grants, modified share‑recycling rules, no single‑trigger acceleration, and anti‑repricing language) which mitigate some common stockholder concerns about excessive dilution or opportunistic repricing. Approving the Plan also permits the Company to offer incentive stock options (Section 422) where tax treatment is relevant. The primary risk for stockholders is dilution and potential overhang given recent high grant activity and large one‑time awards; investors should weigh that dilution against management’s need to retain talent and the Company’s growth plan. The Board recommends FOR on the basis that the proposed reserve is adequate for anticipated hiring and retention needs and because the Plan’s design incorporates best‑practice governance protections. Sophisticated investors will evaluate the proposal by comparing the requested reserve and historical burn rate against the Company’s hiring plan, projected performance, and balance‑sheet position following recent divestitures, and may seek quantitative limits or additional disclosure if concerned about future issuance levels.

The proposal requests stockholder approval of an amendment to the Company’s Amended and Restated 2017 Employee Stock Purchase Plan to add 1,200,000 shares to the ESPP reserve. Management argues this increase is necessary to continue offering a broadly available, discounted purchase vehicle that materially supports retention and employee ownership; the Board notes historical ESPP purchase volumes (≈599k in 2025, ≈516k in 2024 and ≈470k in 2023) and projects the additional shares will cover demand for roughly three years under expected participation and contribution rates. The amendment does not change other ESPP terms (85% look‑back pricing, six‑month offering periods, eligibility rules and contribution limits), and the Board represents the change as a practical, market‑standard update to maintain the program. The principal downside for stockholders is dilution: adding 1.2M shares increases overhang modestly relative to the Company’s outstanding share base. The Board recommends FOR on the basis that the ESPP is a key element of non‑executive compensation and recruitment; shareholders concerned about dilution should weigh the modest incremental share request against the program’s role in broad‑based employee alignment and the relatively small number of shares requested compared with total outstanding shares.